Cargando…

Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases

PURPOSE: To assess the long-term effects of prolonged-release (PR) fampridine tablets (dalfampridine extended release) in clinical practice in patients with multiple sclerosis (MS) with walking impairment. PATIENTS AND METHODS: MS patients with walking impairment deemed candidates for treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prugger, Michael, Berger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810492/ https://www.ncbi.nlm.nih.gov/pubmed/24187513 http://dx.doi.org/10.2147/PROM.S42957

Ejemplares similares

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016)

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
por: Sola-Valls, Núria, et al.
Publicado: (2018)

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report
por: Müller, Mona Klara Ros, et al.
Publicado: (2022)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study
por: Jacques, François, et al.
Publicado: (2018)

Fampridine and quality of life in individuals with multiple sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2016)

A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
por: Mitsikostas, Dimos D., et al.
Publicado: (2021)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
por: Castelnovo, Giovanni, et al.
Publicado: (2021)

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain
por: Ahmedzai, Sam H., et al.
Publicado: (2014)

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study
por: Mamoei, Sepehr, et al.
Publicado: (2021)

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
por: Zeller, D, et al.
Publicado: (2014)

Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
por: Moghadasi, Abdorreza Naser
Publicado: (2021)

Real world evidence of long-term benefits from allergen-specific immunotherapy (AIT)
por: Scadding, Guy
Publicado: (2021)

Determinants of severe QT(c) prolongation in a real-world gerontopsychiatric setting
por: Schulze Westhoff, Martin, et al.
Publicado: (2023)

Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children
por: Howard, Richard F, et al.
Publicado: (2020)

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Dissolution of Intact, Divided and Crushed Circadin Tablets: Prolonged vs. Immediate Release of Melatonin
por: Chua, Hui Ming, et al.
Publicado: (2016)

Long-term effectiveness and safety of self-management of oral anticoagulants in real-world settings
por: Menéndez-Jándula, Bárbara, et al.
Publicado: (2019)

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
por: Keune, Philipp M., et al.
Publicado: (2015)

Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment
por: Ahdab, Rechdi, et al.
Publicado: (2019)

The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings
por: Athyros, Vasilios G., et al.
Publicado: (2012)

Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers
por: Ait Abdellah, Samira, et al.
Publicado: (2023)

Relationship Between Dissolution Rate in Vitro and Absorption Rate in Vivo of Ketamine Prolonged-Release Tablets
por: Weiss, Michael
Publicado: (2023)

Correction to: Long-term effectiveness and safety of self-management of oral anticoagulants in real-world settings
por: Menéndez-Jándula, Bárbara, et al.
Publicado: (2019)

Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
por: Patti, Francesco, et al.
Publicado: (2020)

Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting
por: Chang, Hui-Min, et al.
Publicado: (2022)

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
por: Scheidel, Bernhard, et al.
Publicado: (2017)

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
por: Kanhai, Kawita M. S., et al.
Publicado: (2019)

Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting
por: Kaur, Parjeet, et al.
Publicado: (2016)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

Evaluation and Optimization of Prolonged Release Mucoadhesive Tablets of Dexamethasone for Wound Healing: In Vitro–In Vivo Profiling in Healthy Volunteers
por: Javed, Qurrat ul Ain, et al.
Publicado: (2022)

Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
por: Zirpel, Johanna J., et al.
Publicado: (2021)

Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
por: Lemoine, Patrick, et al.
Publicado: (2011)

Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
por: Lintunen, Jonne, et al.
Publicado: (2021)

Refinement and preliminary evaluation of two tablet‐based tests of real‐world visual function
por: Jones, Pete R, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f41u56i9jfuutp9702gbf0pdlm